Digital transformation has long been a priority for all life science companies and it has been made even more pressing by the current health emergency caused by COVID-19.
New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho